

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/415, 31/05, 31/065, 35/20, 39/395, 33/00		A2	(11) International Publication Number: WO 97/34599
			(43) International Publication Date: 25 September 1997 (25.09.97)
(21) International Application Number: PCT/US97/04244		(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 20 March 1997 (20.03.97)		<p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
(30) Priority Data: 08/621,169 20 March 1996 (20.03.96) US			
(71) Applicant: CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 55 Shattuck Street, Boston, MA 02115 (US).			
(72) Inventors: LENCER, Wayne, I.; 60 Louders Lane, Jamaica Plain, MA 02130 (US). BRUGNARA, Carlo; 33 Aberdeen Street, Newton Highlands, MA 02161 (US). ALPER, Seth; 74 Orchard Street, Jamaica Plain, MA 02130 (US).			
(74) Agent: KINDREGAN, Helen, C.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).			

(54) Title: USE OF CLOTRIMAZOLE AND RELATED COMPOUNDS IN THE TREATMENT OF DIARRHEA

(57) Abstract

The invention relates to the pharmaceutical or veterinary use and compositions of aromatic compounds in preventing or treating diarrhea or scours. Said compounds correspond to formula (I) and are most preferably clotrimazole or its metabolites (particularly 2-chloro-phenyl-bisphenyl-methanol) or are miconazole or econazole.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

USE OF CLOTRIMAZOLE AND RELATED COMPOUNDS IN THE TREATMENT OF DIARRHEA

5

Background of the Invention

Acute and chronic diarrheas represent a major medical problem in many areas of the world. Diarrhea is both a significant factor in malnutrition and the leading cause of death (5,000,000 deaths/year) in children less than five years old. Secretory diarrheas are also a dangerous condition in patients of acquired immunodeficiency syndrome (AIDS) and chronic inflammatory bowel disease (IBD). 16 million travelers to developing countries from industrialized nations every year develop diarrhea, with the severity and number of cases of diarrhea varying depending on the country and area of travel. The major medical consequences of diarrheal diseases include dehydration, acidosis, death and impaired growth.

Diarrhea in barn animals and pets such as cows, pigs and horses, sheep, goats, cats and dogs, also known as scours, is a major cause of death in these animals. Diarrhea can result from any major transition, such as weaning or physical movement. One form of diarrhea is characterized by diarrhea in response to a bacterial or viral infection and generally occurs within the first few hours of the animal's life.

Although the major consequences of diarrheal diseases are very similar, there are numerous causes of diarrhea. Secretory and exudative diarrhea are primarily caused by bacterial or viral infections. The most common diarrheal causing bacteria is enterotoxogenic E-coli (ETEC) having the K99 pilus antigen. Common viral causes of diarrhea include rotavirus and coronavirus. Other infectious agents include cryptosporidium, giardia lamblia, and salmonella, among others.

The treatment for diarrhea depends on the patient and the infection source. Diarrhea which is found in travelers to industrialized nations (travelers diarrhea) frequently is caused by bacterial pathogens which are acquired through ingestion of fecally contaminated food and/or water. Approximately 50-75% of these cases are attributed to ETEC. Although traveler's diarrhea is painful, it is generally not life-threatening and often the symptoms last only 3-5 days. The symptoms include urgent diarrhea, abdominal cramps, nausea and fever. The most effective course of treatment for traveler's diarrhea is the administration of antibiotics in conjunction with oral rehydration. It has been shown that prophylactic administration of antibiotics drastically reduces the number of travelers experiencing symptoms of diarrhea. However, routine

administration of antibiotics is not suggested as it may cause resistant strains of a bacteria to develop. Other treatment methods include administration of bismuth subsalicylate, often taken in the form of Pepto-Bismal, diphenoxylate and loperamide.

Diarrhea in AIDS patients is a very serious condition which causes wasting and may be an important factor in the decline of these patients. AIDS patients often develop diarrhea due to enteric infections which their immune system is not capable of fighting off, but AIDS patients may also develop diarrhea by AIDS enteropathy. AIDS enteropathy is a disorder characterized by diarrhea without the involvement of secondary infections. It is caused by the human immunodeficiency virus (HIV) infection of the small bowel mucosal cells and colonic mucosal cells. The most common infective agent causing diarrhea due to enteric infection in AIDS patients is cryptosporidium. The methods for treating diarrhea in AIDS patients include administration of antibiotics and administration of immunoglobulins or an immunoglobulin enriched fraction of bovine colostrum. Colostrum, which is the first milk produced by mammals after birthing is enriched with antibodies.

Acute diarrhea or scours, is a main cause of death in many newborn barn animals such as calves and pigs. Scours is often caused by ETEC with a K99 pilus antigen. Infection with the ETEC causes hypersecretion of fluid and electrolytes. Hypersecretion in turn causes dehydration and pH imbalance which may result in death of the newborn calf or pig.

Newborn barn animals are also susceptible to viral infectious agents causing scours. Infections with rotavirus and coronavirus are common in newborn calves and pigs. Rotavirus infection often occurs within 12 hours of birth. Symptoms of rotaviral infection include excretion of watery feces, dehydration and weakness. Coronavirus which causes a more severe illness in the newborn animals, has a higher mortality rate than rotaviral infection. Often, however, a young animal may be infected with more than one virus or with a combination of viral and bacterial microorganisms at one time. This dramatically increases the severity of the disease.

Generally the best protection for a newborn barn animal from viral or bacterial infection is the consumption of colostrum. If the mother animal has been exposed to these infectious agents then the colostrum will contain antibodies, which are often sufficient to protect the newborn from contracting the diseases. Sometimes, however, this is not sufficient and the animals need further protection. A common method of treatment includes administration of a concentrated colostrum solution or an immunoglobulin fraction isolated from a colostrum


solution. This oral treatment may be combined with rehydration salts. Although these methods have improved the morbidity and mortality rate of newborn animals having scours, there still exists a need for more effective treatments.

Certain imidazoles such as clotrimazole are agents which have been used both topically and systemically as antifungals. More recently, studies have identified other uses for such imidazoles. U.S. patent no. 5,273,992 revealed that these imidazoles regulate Ca^{++} activated K^+ channels in erythrocytes, and are thus useful in treating sickle cell anemia, which involves the inhibition of potassium transport. These imidazoles have also been found to be effective in inhibiting endothelial and/or vascular smooth muscle cell proliferation. The results of this finding are described in U.S. patent no. 5,358,959 and U.S. serial no. 08/018,840, which discloses using clotrimazole for treating atherosclerotic and angiogenic conditions, respectively. Nonimidazole metabolites and analogs of the foregoing compounds also have been described as useful in treating the foregoing conditions (see U.S. serials nos. 08/307,874 and 08/307,887).

Summary of the Invention

The present invention provides methods and products for treating diarrhea and scours. It has been discovered that aromatic compounds are effective in treating patients with diarrhea. These compounds are potent inhibitors of secretagogue-stimulated transepithelial electrogenic chloride secretion in intestinal cells.

According to one aspect of the invention, a method for treating diarrhea of diverse etiology is provided. The method involves administering to a subject who is in need of such treatment, an aromatic compound of the invention in an amount effective to inhibit the diarrhea. Preferably the compound is administered orally in conjunction with oral rehydration fluids. The aromatic compounds useful in the invention have the following formula:



wherein $n = 0-3$; wherein $p = 0$ or 1 ; wherein X is selected from the group consisting of $(CH_2)_m$ ($m=0, 1, 2$, or 3), $CH=CH$, $C\equiv C$, SCH_2 , OCH_2 , and $NOCH_2$; wherein R' is selected from the group consisting of H , OH , SH , NO_2 , CN , CHO , ONH_2 , CCH , COR'' , CO_2H , CO_2R'' , OR'' , SR'' , $NR''R''$, $CONR''R''$, heteroaryl, and $CONR''(OCH_3)$; wherein Ar^1 is selected from the group consisting of phenyl, substituted phenyl, and heteroaryl; wherein Ar^2 is selected from the group consisting of phenyl and substituted phenyl; wherein Ar^3 is selected from the group consisting of phenyl, substituted phenyl, biphenyl, bibenzyl, and naphthyl; wherein the phenyl substituent is selected from the group consisting of Cl , F , Br , I , R , OR'' , SR'' , NO_2 , CN , CF_3 , $NR''R''$, and CO_2R ; wherein R is selected from the group consisting of straight chain alkyl of $C_{z(z=1-5)}$, substituted straight chain alkyl of $C_{z(z=1-5)}$, branched alkyl of $C_{z(z=1-5)}$, and substituted branched alkyl of $C_{z(z=1-5)}$; wherein the alkyl substituent is selected from the group consisting of Cl , Br , F , I , OH , OCH_3 , SH , SCH_3 , NH_2 , $NHCH_3$, and $N(CH_3)_2$; and wherein R'' is selected from the group consisting of hydrogen and R .

A heteroaryl group includes but is not limited to furanyl, imidazole, pyridinyl, thiophenyl, indolyl, imidazolyl, and quinolyl.

In a preferred embodiment of the invention the aromatic compound is clotrimazole or a metabolite of clotrimazole.

Other aromatic compounds useful in the invention are miconazole and econazole.

In one embodiment of the invention the foregoing aromatic compounds may be administered in combination with other anti-diarrheal agents. In another embodiment the aromatic compounds may be administered in combination with other anti-scours agents.

According to one embodiment of the invention the subject in need of such treatment is a subject who has symptoms of diarrhea or scours. In another embodiment of the invention, the subject in need of such treatment is a subject at risk of developing diarrhea or scours.

According to another aspect of the invention, pharmaceutical preparations are provided. These pharmaceutical preparations include the aromatic compounds of the invention together with an anti-diarrheal agent. In one embodiment, the aromatic compounds useful according to the invention have the general formula provided above. In another embodiment, the aromatic compounds useful according to the invention are selected from the group consisting of miconazole and econazole. In yet another embodiment, the aromatic compounds useful according to the invention have the above-disclosed general formula, but wherein R' and AR^1 do

not include imidazoles. Preferably the pharmaceutical composition of the invention may be administered orally.

According to another aspect of the invention, veterinary preparations are provided. These veterinary preparations include the aromatic compounds useful according to the invention
5 together with an anti-scours preparation. In one embodiment, the aromatic compounds of the invention have the general formula provided above. In another embodiment, the aromatic compounds useful according to the invention are selected from the group consisting of miconazole and econazole. In yet another embodiment, the aromatic compounds useful according to the invention have the above-disclosed general formula, but wherein R' and AR¹ do
10 not include imidazoles.

The invention also provides the aromatic compounds of the invention in the manufacture of a medicament for the treatment of diarrhea. In one embodiment, the aromatic compounds of the invention have the above-disclosed general formula, but do not include clotrimazole. In another embodiment, the aromatic compounds useful in the manufacture of a medicament for the
15 treatment of diarrhea have the above-disclosed general formula, but wherein R' and AR¹ do not include imidazoles.

The invention also provides the aromatic compounds of the invention in the manufacture of a medicament for the treatment of scours. In one embodiment, the aromatic compounds of the invention have the above-disclosed general formula but do not include clotrimazole.

20 In another embodiment, the aromatic compounds useful in the manufacture of a medicament for the treatment of scours have the above-disclosed general formula, but wherein R' and AR¹ do not include imidazoles.

Brief Description of the Drawings

25 Figure 1 is a bar graph depicting the effect of clotrimazole in the inhibition of cAMP and Ca⁺⁺ dependent Cl⁻ secretion in T84 cells.


Figure 2 is a graph showing the effect of clotrimazole on the inhibition of base line and Ca⁺⁺ - stimulated ⁸⁶Rb efflux from T84 monolayers.

Detailed Description of the Invention

30 The invention involves a method and product for reducing the symptoms of diarrhea or preventing diarrhea in a subject at risk for developing diarrhea. The compounds of the invention

are aromatic compounds. The aromatic compounds useful according to the invention are provided in a pharmaceutical preparation and a veterinary preparation. The aromatic compounds of the invention are also useful in a method for treating diarrhea and scours as well as a method for preventing diarrhea and scours.

5 The aromatic compounds known to be useful in the invention have the following formula:




15 wherein $n = 0-3$; wherein $p = 0$ or 1 ; wherein X is selected from the group consisting of $(\text{CH}_2)_m$ ($m=0,1,2$, or 3), $\text{CH}=\text{CH}$, $\text{C}\equiv\text{C}$, SCH_2 , OCH_2 , and NOCH_2 ; wherein R' is selected from the group consisting of H , OH , SH , NO_2 , CN , CHO , ONH_2 , CCH , COR'' , CO_2H , $\text{CO}_2\text{R}''$, OR'' , SR'' , $\text{NR}''\text{R}''$, $\text{CONR}''\text{R}''$, heteroaryl, and $\text{CONR}''(\text{OCH}_3)$; wherein Ar^1 is selected from the group consisting of phenyl, substituted phenyl, and heteroaryl; wherein Ar^2 is selected from the group consisting of phenyl and substituted phenyl; wherein Ar^3 is selected from the group consisting of phenyl, substituted phenyl, biphenyl, bibenzyl, and naphthyl; wherein the phenyl substituent is selected from the group consisting of Cl , F , Br , I , R , OR'' , SR'' , NO_2 , CN , CF_3 , $\text{NR}''\text{R}''$, and CO_2R ; wherein R is selected from the group consisting of straight chain alkyl of $\text{C}_{z(z=1-5)}$, substituted straight chain alkyl of $\text{C}_{z(z=1-5)}$, branched alkyl of $\text{C}_{z(z=1-5)}$, and substituted branched alkyl of $\text{C}_{z(z=1-5)}$; wherein the alkyl substituent is selected from the group consisting of Cl , Br , F , I , OH , OCH_3 , SH , SCH_3 , NH_2 , NHCH_3 , and $\text{N}(\text{CH}_3)_2$; and wherein R'' is selected from the group consisting of hydrogen and R .




A heteroaryl group includes but is not limited to furanyl, imidazole, pyridinyl, thiophenyl, indolyl, imidazolyl, and quinolyl.

In one embodiment the aromatic compound of the invention is clotrimazole, which has the following chemical structure:


In one embodiment the aromatic compound of the invention is clotrimazole, which has the following chemical structure:




Other aromatic compounds believed useful according to the invention are clotrimazole metabolites, which have the following chemical structure:



Other aromatic compounds believed useful according to the invention include miconazole and econazole which have the following structures:



Econazole



Miconazole

The aromatic compounds of the invention are commercially available compounds, are derived from commercially available compounds or are synthesized de novo using routine chemical synthetic procedures known to those of ordinary skill in the art.

Diarrhea, as used herein, indicates a medical syndrome which is characterized by the symptoms of diarrhea or scours. Diarrhea may be divided into three categories based on the underlying mechanism: exudative, decreased absorption, and secretory. Exudative diarrheas result from inflammatory processes leading to impaired colonic absorption, and outpouring of cells and colloid caused by such disorders as ulcerative colitis, shigellosis, and amebiasis.

Disorders of decreased absorption include osmotic, anatomic derangement, and motility disorders. Osmotic diarrhea can occur as a result of digestive abnormalities such as lactose intolerance. Anatomic derangement results in a decreased absorption surface caused by such procedures as subtotal colectomy and gastrocolic fistula. Motility disorders result from
5 decreased contact time resulting from such diseases as hyperthyroidism and irritable bowel syndrome. Secretory diarrhea is characterized by the hypersecretion of fluid and electrolytes from the cells of the intestinal wall. In classical form, the hypersecretion is due to changes which are independent of the permeability, absorptive capacity and exogenously generated osmotic gradients within the intestine. However, all forms of diarrhea may manifest a secretory
10 component.

The methods and products of the invention are particularly useful in treating diarrhea which is secretory. However, the methods and products of the invention may also be used in combination with other treatment methods which are known in the art to treat diarrhea caused by decreased absorption or inflammation. The compounds of the invention are involved in
15 regulating Cl^- secretion and can function alone or when used in combination with other treatment methods to decrease net fluid secretion even when this is due primarily to abnormalities in absorption or inflammation.

The methods and products of the invention are useful in preventing diarrhea and scours in subjects at risk of developing these disorders. Subjects at risk of developing diarrhea and scours
20 are those subjects which have a high likelihood of exposure to the bacterial and viral microorganisms which cause these symptoms. For example, approximately 1/3 of travelers to developing countries will develop diarrhea; infection with rotavirus is one of the leading causes of death in infants in developing countries; patients with HIV have a greater than 50% chance of developing diarrhea, and many newborn calves and pigs develop scours. Patients with
25 inflammatory bowel disease develop recurrent diarrhea.

The methods and products of the invention are also useful in treating subjects who already exhibit the symptoms of diarrhea and scours. Once a subject has been exposed to a microorganism causing the symptoms, the subject may be treated with the methods and products of the present invention in order to reduce the symptoms. The symptoms of diarrhea include
30 bowel irregularity, fecal fluid rich in sodium or potassium, fluid feces, dehydration, fever, loss of body weight, headache, anorexia, vomiting, malaise and myalgia. The symptoms of scours include a loss of body weight or failure to grow, dehydration, malodorous feces, fluid feces,

feces containing pieces of partially digested milk or semisolid material, and feces of a yellow-white or gray color.

One product of the invention is a veterinary preparation of an aromatic compound of the invention, used alone or combined with an anti-scours agent. An anti-scours agent is a composition which is known to be useful in preventing or inhibiting the symptoms of scours. Known compositions include, for example, colostrum extracts, such as those described in U.S. patent no. 4,377,569 and Canadian patent no. 1,175,352 and widely commercially available (e.g. Soluble Colostrum Powder, by VedCo, Inc., St. Joseph MO; Colostrum Bolus II, by RX Veterinary Products, Kansas City MO, etc.); an immunological preparation of colostrum isolated from milk-producing mammals which may have been immunized against certain diarrheal causing microorganisms, such as those described in U.S. patent no. 4,834,974, Australian patent no. 39340/89, Australian patent no. 52547/90, and German patent no. 1,560,344; microorganism specific immunological preparations, including microorganism specific hybridoma-derived monoclonal antibodies such as those described in Sherman et al., Infection and Immunity, V. 42 (2), P. 653-658 (1983) and a bovine immunoglobulin fraction prepared from bovine plasma or clear bovine serum such as the fraction described in U.S. patent no. 3,984,539; oral rehydration fluids and/or replacement electrolyte compositions which are widely commercially available in the form of dry compositions or liquid solutions prepared for oral or intravenous administration (e.g. Electrolyte H, by Agri-Pet Inc., Aubrey TX; Electrolyte Powder 8x, by Phoenix Pharmaceutical Inc, St. Joseph MO; Electrolyte Solution Rx, by Lextron Inc., Greeley CO, ProLabs LTD, St. Joseph MO, and VetTek Inc., Blue Springs MO; Calf Rehydrate, by Durvet Inc., Blue Springs MO, etc.) and antibiotic compositions which are commercially available (e.g. BIOSOL® Liquid, by The UpJohn Company Animal Health Division, Kalamazoo MI; AMOXI-BOL®, by SmithKline-Beecham Animal Health, Exton PA; 5-WAY CALF SCOUR BOLUS™, by Agri Laboratories LTD, St. Joseph MO; 1-A-DAY CALF SCOUR BOLUS, by A.H.A.; GARACIN® PIG PUMP, by Schering-Plough Animal Health Corporation, Kenilworth NJ, etc.).

In one embodiment, the aromatic compounds useful in the veterinary preparation include miconazole, econazole, and the aromatic compounds of the general formula provided above.

In another embodiment, the aromatic compounds useful in the veterinary preparation include the aromatic compounds of the general formula provided above, but wherein R' and AR¹ do not include imidazoles.

In one embodiment, the veterinary preparation is a dry preparation of the aromatic compound of the invention and an antiscours agent. The dry preparation may be administered directly or may be hydrated and/or diluted in a liquid solution prior to administration. In another embodiment, the veterinary preparation is a liquid solution of the compound of the invention and
5 an anti-scours agent.

Another product of the invention is a pharmaceutical preparation of an aromatic compound of the invention and an anti-diarrheal agent. An anti-diarrheal agent includes, for example, an immunoglobulin preparation from bovine colostrum; lomotil; an intravenous or oral rehydration fluid; a dry rehydration composition salt; an electrolyte replacement composition (in
10 dry or liquid form); an oral or intravenous sugar-electrolyte solution or dry composition; an antibiotic such as tetracycline, trimethoprim or sulfamethoxazole; a quinolone drug such as norfloxacin or ciprofloxacin, bismuth subsalicylate, diphenoxylate; and loperamide.

In one embodiment, the aromatic compounds useful in the pharmaceutical preparation include miconazole, econazole, and the aromatic compounds of the general formula provided
15 above.

In another embodiment, the aromatic compounds useful in the pharmaceutical preparation include the aromatic compounds of the general formula provided above, but wherein R' and AR¹ do not include imidazoles.

In one embodiment the pharmaceutical preparation is a dry preparation of the aromatic
20 compound of the invention and an anti-diarrheal agent. The dry preparation may be administered directly or may be hydrated and/or diluted in a liquid solution prior to administration. In another embodiment the pharmaceutical preparation is a liquid solution of the aromatic compound of the invention and an anti-diarrheal agent.

A subject as used herein, means humans, primates, horses, cows, sheep, pigs, goats, cats
25 and dogs.

The time of administration of the aromatic compounds useful according to the invention varies depending upon the purpose of the administration. When the compounds of the invention are administered in order to prevent the development of diarrhea in subjects traveling to areas with high risk of exposure to infectious agent or subjects otherwise exposed to diarrhea causing
30 agents, the compounds should be administered at about the time that the subject is exposed to the risk or the high risk area. When the compounds are administered to subjects in order to prevent the development of scours, the veterinary preparation should be administered within the first 12

hours after birth, and preferably within the first 4 hours after birth. When the compounds of the invention are used to treat subjects having symptoms of diarrhea or scours, the compounds may be administered at any point while the subject is experiencing symptoms, and preferably as soon as the symptoms develop.

5 When administered, the formulations of the invention are applied in pharmaceutically acceptable amounts and in pharmaceutically acceptable compositions. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic ingredients. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically
10 acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulfonic, tartaric, citric, methane sulfonic, formic, malonic, succinic, naphthalene-2-sulfonic, and benzene sulfonic. Also, pharmaceutically acceptable salts
15 can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.

Suitable buffering agents include: acetic acid and a salt (1-2% W/V); citric acid and a salt (1-3% W/V); boric acid and a salt (0.5-2.5% W/V); and phosphoric acid and a salt (0.8-2% W/V).

20 Suitable preservatives include benzalkonium chloride (0.003-0.03% W/V); chlorobutanol (0.3-0.9% W/V); parabens (0.01-0.25% W/V) and thimerosal (0.004-0.02% W/V).

The active compounds of the present invention may be pharmaceutical compositions having a therapeutically effective amount of an aromatic compound of the general formula provided above in combination with an anti-diarrheal agent, optionally included in a
25 pharmaceutically-acceptable carrier. The active compounds of the present invention also may be veterinary compositions having a therapeutically effective amount of an aromatic compound of the general formula provided above in combination with an anti-scours agent, optionally included in a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid filler, dilutants or
30 encapsulating substances which are suitable for administration to a human or other animal. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the

pharmaceutical compositions also are capable of being commingled with the compound of the present invention, with the anti-diarrheal or anti-scours agents, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

5 A common administration vehicle (e.g., pill, tablet, bolus, powder or solution for dilution, pig pump, implant, injectable solution, etc.) would contain both the compounds useful in this invention and the anti-diarrheal or anti-scours agent. Thus, the present invention provides pharmaceutical or veterinary compositions, for medical or veterinary use, which comprise the active compounds of the invention together with one or more pharmaceutically acceptable
10 carriers thereof and other therapeutic ingredients.

 The formulations of the invention are administered in effective amounts. An effective amount is one sufficient to inhibit the Cl^- secretion of intestinal epithelial cells, thereby effectively decreasing the secretory response, thereby resulting in a decrease in diarrhea or scours and/or the symptoms thereof. Effective amounts will depend, of course, on the particular
15 condition being treated; the severity of the condition; individual patient parameters including age, physical condition, size and weight; concurrent treatment; frequency of treatment; and the mode of administration. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical judgment,
20 particularly if acute diarrhea or scours are the dominant clinical manifestation.

 Dosage may be adjusted appropriately to achieve desired drug plasma levels. Generally, daily oral doses of active compounds will be from about 0.01 milligrams/kg per day to 1000 milligrams/kg per day. It is expected that oral doses in the range of 50 to 500 milligrams/kg, in one or several administrations per day, will yield the desired results. In the event that the
25 response in a subject is insufficient at such doses, even higher doses (or effective higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compounds.

 A variety of administration routes are available. The particular mode selected will
30 depend of course, upon the particular drug selected, the severity of the diarrhea or scours being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable,

meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal, transdermal or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intramuscular, or infusion. Intravenous and intramuscular routes are not particularly
5 suited for long term therapy and prophylaxis. They could, however, be preferred in emergency situations. Oral administration will be preferred for prophylactic treatment because of the convenience to the subject as well as the dosing schedule.

The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step
10 of bringing the active compounds into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units such as
15 capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquors or non-aqueous liquids such as a syrup, an elixir, or an emulsion. Active ingredients administered orally may be in any form suitable for oral administration, e.g., a pill, tablet, bolus, drinking solution, liquid or powder composition to be diluted or mixed with food, pig pump, etc.

20 Compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound, which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable
25 diluent or solvent, for example as a solution in 1, 3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
30 Carrier formulations suitable for oral, subcutaneous, intravenous, intramuscular, etc. can be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the active compounds of the invention, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include

5 polymer based systems such as polylactic and polyglycolic acid, polyanhydrides and polycaprolactone; nonpolymer systems that are lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-, di- and triglycerides; hydrogel release systems; silastic systems; peptide based systems; wax coatings, compressed tablets using conventional binders and excipients, partially fused implants and the like. Specific examples

10 include, but are not limited to: (a) erosional systems in which the polysaccharide is contained in a form within a matrix, found in U.S. Patent Nos. 4,452,775 (Kent); 4,667,014 (Nestor et al.); and 4,748,034 and 5,239,660 (Leonard) and (b) diffusional systems in which an active component permeates at a controlled rate through a polymer, found in U.S. Patent Nos. 3,832,253 (Higuchi et al.) and 3,854,480 (Zaffaroni). In addition, a pump-based hardware

15 delivery system can be used, some of which are adapted for implantation.

Use of a long-term sustained release implant may be particularly suitable for treatment of diarrhea in immunodeficient patients, who need continuous administration of the compositions of the invention. "Long-term" release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for at least 30 days, and preferably

20 60 days. Long-term sustained release implants are well known to those of ordinary skill in the art and include some of the release systems described above.

25

Examples

Example 1: Clotrimazole inhibits water and electrolyte secretion in intestinal epithelial cells.

The biochemical basis of secretory diarrhea involves intestinal Cl^- secretion in intestinal crypt cells. Under normal conditions, Cl^- ions are maintained within intestinal crypt cells at

30 levels above their electrochemical potential by primarily and secondarily active transport mechanisms such as the Na/K ATPase pumps and Na/K/2Cl cotransporters. Cl^- is transported

into the lumen from the intestinal crypt cells through apical Cl^- channels. Intracellular levels of K^+ , cAMP, cGMP, and Ca^{++} are all involved in regulating the secretory response.

T84 cells were used to determine whether clotrimazole regulates Cl^- secretion in intestinal crypt cells. T84 cells form confluent monolayers of columnar epithelia that exhibit high transepithelial resistances, polarized apical and basolateral membranes, and cAMP and Ca^{++} regulated Cl^- secretory pathways analogous to those found in native intestine.

Methods

Growth of T84 cells: T84 cells obtained from ATCC were cultured and passaged in equal parts of dulbecco's modified eagle's medium (DMEM), 1g/1D-glucose) and Hams F-12 nutrient mixture, supplemented with 5% newborn calf serum, 15 mM HEPES, 14 mM Na HCO_3 , 40mg/l penicillin, 8mg/l ampicillin, 0.90 mg/l streptomycin. Cells were seeded at confluent density onto 0.33 cm^2 or 5 cm^2 Transwell inserts (Costar, Cambridge, MA) coated with dilute rat collagen solution as previously described (Lencer et al., J. Clin. Invest., 92: 2941-2951 (1993); Lencer et al., J. Cell Biol. 117: 1197-1209 (1992). Transepithelial resistances attain stable levels (>1000 Ohms. cm^2) after 7 days. The development of high transepithelial resistances correlated with the formation of confluent monolayers with well-developed tight junctions as assessed by morphological analysis, and with the ability of monolayers to secrete Cl^- (Madara et al., Gastro. 92: 1133-1145 (1987).

Electrophysiology (measurement of electrogenic Cl^- secretion): Confluent monolayers were transferred to Hanks Buffered Salt Solution (HBSS) containing 0.185 g/l CaCl_2 , 0.098 g/l MgSO_4 , 0.4 g/l KCl, 0.06 g/l KH_2PO_4 , 8 NaCl, 0.048 g/l Na_2HPO_4 , 1 g/l glucose, and 10nM HEPES, pH 7.4. Serosal and mucosal reservoirs were interfaced with Calomel and Ag-Ag Cl electrodes via 5% agar bridges made with Ringer's buffer. Transepithelial resistance was measured using a dual voltage clamp device to apply 25 or 50 μA current pulses. Short circuit current (ISC) was calculated using Ohms law as previously described (Lencer et al., J. Clin. Invest. 92: 2941-2951 (1993); Lencer et al. J. Cell Biol. 117: 1197-1209 (1992).

Results:

Clotrimazole reversibly inhibits Cl^- secretion elicited by Ca^{++} - or cAMP- dependant agonists in T84 cells: Previous studies have shown that Cl^- secretion in T84 cells is controlled by K^+ efflux pathways which are biophysically and pharmacologically distinct from one another.

One pathway participates in the secretory response to cAMP-dependent agonists and displays sensitivity to Ba^{++} salts (McRoberts, et al., *J. Biol. Chem.* 260: 14163-14172 (1985); Reenstra, *Am J. Physiol.* 264: C161-168 (1993)). The other mediates the response to Ca^{++} -dependent agonists, and is Ba^{++} -insensitive. Several pathway specific agonists of K^+ channels are useful for determining whether a particular compound is functioning through a cAMP or Ca^{++} specific pathway. For instance, vasoactive intestinal peptide (VIP) and cholera toxin are cAMP mediated agonists of the K^+ channel, whereas, carbachol is a Ca^{++} -dependent agonist of the Ca^{++} regulated K^+ channels. The pathway by which a particular inhibitor of Cl^- secretion in T84 cells is functioning may be identified by measuring the ability of the inhibitor to modify transepithelial resistances in T84 cells which have been treated with VIP or carbachol to stimulate Cl^- secretion.

T84 cells were grown as described above and Cl^- secretion was stimulated by the addition to the media of either carbachol (100mM) or VIP (5nM). The cells were then treated with BaCl (3mM), charybdotoxin (100nM), or clotrimazole (33mM). The short circuit current (ISC) was determined for the various inhibitor treatments as a percentage of the control in the absence of inhibitor (Fig. 1). BaCl strongly inhibited the secretory response to the cAMP mediated agonist VIP, but had no apparent affect on the secretory response elicited by the Ca^{++} -dependent agonist carbachol. In contrast, the scorpion venom Charybdotoxin strongly inhibited the secretory response elicited by carbachol, but had minimal affects on Cl^- secretion elicited by VIP. However, clotrimazole inhibited the Cl^- secretory responses to both agonists. Inhibition of Cl^- secretion by clotrimazole was fully reversible ($96 \pm 2\%$, $n = 4$) after 60 min recovery in the presence of 0.01 mg/ml bovine serum albumin.

To examine possible effects of clotrimazole on the synergy between cAMP and Ca^{++} -mediated agonists, monolayers, initially stimulated with VIP were allowed to reach steady-state levels of secretion and then additionally exposed to carbachol (100 μ M). Clotrimazole was slightly more effective in inhibiting the secretory response to carbachol than to cAMP with IC_{50} values of 3 and 8 μ M, respectively. When the effects of clotrimazole on cAMP- and Ca^{++} -dependent secretory pathways were examined on the same monolayers., inhibition of the synergistic response to VIP plus carbachol was found to parallel the inhibition of secretion promoted by Ca^{++} agonists alone. In low doses ($=10^{-7}$ or less), clotrimazole potentiated slightly (by 5-10%) the Cl^- -secretory responses to either agonist. clotrimazole inhibited effectively the

secretory response to cholera toxin (20 nM, a cAMP-dependent agonist) and *E. Coli* heat-stable toxin (100 nm, a cGMP-agonist) (IC₅₀ values of 10 μ M and 15 μ M, respectively).

The effect of clotrimazole on K⁺ conductances was also examined by isotopic flux studies using ⁸⁶RB. T84 cells were grown in the presence of a cAMP agonist, VIP, or a Ca⁺⁺ mediated agonist (Thapsigargin). Clotrimazole was added and ⁸⁶RB efflux was measured. Clotrimazole significantly inhibited baseline and Ca⁺⁺ stimulated ⁸⁶RB efflux in the presence of both cAMP and Ca⁺⁺ mediated agonists compared to those cells which were not treated with clotrimazole.

Other aromatic compounds of the invention were found to inhibit chloride secretion. Although clotrimazole was the most potent inhibitor tested of cAMP and Ca⁺⁺ elicited Cl⁻ secretion, ketoconazole, econazole, miconazole, and 2-chlorophenyl-bis-phenyl methanol also were effective at inhibiting chloride secretion.

Taken together, these studies indicate that clotrimazole inhibits Cl⁻ secretion elicited by cAMP or Ca⁺⁺ mediated K⁺ channels in T84 cells .

Example 2: Clotrimazole acts at distal steps in the cAMP and Ca⁺⁺-dependent signal transduction pathways

To determine the site of clotrimazole action, the effects of clotrimazole pretreatment were examined on monolayers stimulated with agonists that initiate Cl⁻ secretion at sequential steps in the cAMP signalling cascade. T84 monolayers were preincubated in HBSS in the presence or absence of clotrimazole (33 μ M) and then stimulated with either 5 μ M VIP (which activates adenylate cyclase through heterotrimeric GTPase-linked cell surface receptors), 10 μ M forskolin (which activates adenylate cyclase directly), or 3 mM 8Br-cAMP (a direct stimulator of protein kinase A). Clotrimazole inhibited the secretory response to each of these agonists. These data provide evidence that clotrimazole acts at a step distal to the activation of Protein Kinase A.

Ca⁺⁺-dependent intracellular signaling in T84 and other non-exciteable cells involves recruitment of inositol trisphosphate (IP₃)-dependent intracellular Ca⁺⁺ stores (Halm and Frizzell, *Textbook of Secretory Diarrhea*, Raven Press, 47-58 (1990); Mandel et al., *J. Biol. Chem.* 267: 704-712 (1986); Halm et al., *Am. J. Physiol. (Cell Physiol.* 23) 254:C505-C511 (1988)), and subsequent activation of plasma membrane Ca⁺⁺ influx pathways (Barrett, *Am. J. Physiol. (Cell Physiol.* 34): C859-C868 (1993)). Downstream events may be mediated by [Ca⁺⁺]_i, IP₃, diacylglycerol, or as yet unidentified diffusable factors (Putney and Bird, *Cell*

75:199-201 (1993)). To examine the site of clotrimazole action alone, this signalling, cascade, T84 monolayers pretreated in the presence or absence of clotrimazole (33 μ M) were stimulated with the Ca^{++} -dependent agonists carbachol (100 μ M which elicits both Ca^{++} and IP_3 signals), thapsigargin (5 μ M, which elevates cytoplasmic Ca^{++} via inhibition of ER Ca^{++} -ATPase) 5 (Vandorpe et al., *Biophys. J.* 66:46-58 (1994)), or the Ca^{++} ionophore ionomycin (10 μ M). Clotrimazole inhibited strongly the Cl^- -secretory response to each of these reagents. These data suggest that clotrimazole acts at steps in the secretory response distal to the release of intracellular Ca^{++} stores.

10 **Example 3: Clotrimazole does not affect apical membrane anion conductance or basolateral NaK2Cl cotransporters**

Methods

^{125}I Efflux Studies

15 Confluent monolayers on 5 cm^2 Transwell inserts were used 10-14 days after plating. ^{125}I was measured as an indicator of apical Cl^- , channel and basolateral K^+ channel activity as previously described (Venglarik, et al, *Am. J. Physiol. (Cell Physiol.* 28):C358-C364 (1990). Monolayers were preincubated at 37° C with 4 $\mu\text{Ci/ml}$ ^{125}I in HBSS for 90 minutes, with 33 μM clotrimazole absent or present during the final 30 minutes of this 90 min preincubation period. 20 Clotrimazole pretreatment did not alter ^{125}I loading of the cells. After washing twice in fresh HBSS, 0.5 ml samples were obtained every two min from the apical reservoir and replaced with fresh HBSS. After four baseline samples were obtained, the cells were treated (at $t = 8$ minutes) with vasoactive intestinal peptide (VIP, 5 μM) or thapsigargin (5 μM) to stimulate Cl^- secretion, and an additional 15 timed samples were obtained. Finally, the cell monolayer was 25 rinsed, cut with its support from the polystyrene ring, and the residual cell-associated radioactivity was determined. Monolayers were maintained at 37° C in room air throughout the study. ^{125}I was counted by gamma counting and normalized to percent total uptake as previously described (Venglarik, et al, *Am. J. Physiol. (Cell Physiol.* 28):C358-C364 (1990).

^{86}Rb Uptake Studies

30 Confluent monolayers on 5 cm^2 Transwell inserts were incubated for 30 minutes in HBSS at 37° C. A group of control and CLT treated (33 μM , for 30 min) monolayers were treated with bumetanide (10 μM for 12 min). All monolayers were then treated with VIP (5nM

and shifted to HBSS containing 1 $\mu\text{Ci/ml}$ ^{86}Rb for 3 minutes at 37° C. ^{86}Rb uptake was terminated by washing the inserts in an ice-cold solution containing 100mM MgCl_2 , and 10mM TRIS-CL, pH 7.4. Monolayers were cut from their inserts, placed into scintillation vials, and counted using standard methods.

5

Results

Studies were conducted to determine whether the inhibition of electrogenic Cl^- secretion might occur by blockade of apical membrane Cl^- channels, or blockade of basolaterally situated NaK2Cl cotransporters. To determine if clotrimazole affected ion conductance through apical

10 membrane Cl^- channels, we examined the time course of ^{125}I efflux from T84 monolayers pretreated in the presence or absence of clotrimazole (Venglarik, et al, *Am. J. Physiol. (Cell Physiol. 28):C358-C364* (1990). Clotrimazole had little or no effect on the time course of ^{125}I efflux from monolayers treated with VIP. Rate constants for ^{125}I efflux from monolayers treated or not treated with clotrimazole were indistinguishable (0.0637 vs. 0.0645 %

15 uptake/minute, $n=2$ in duplicate). Clotrimazole had similar lack of effect on ^{125}I efflux stimulated by thapsigargin.

We next tested the effect of clotrimazole on basolateral NaK2Cl cotransporters, as assessed by bumetanide-sensitive ^{86}Rb uptake (Matthews et al., *J. Biol. Chem.* 269:15703-15709 (1994)). Clotrimazole treatment reduced the total amount of ^{86}Rb uptake by $53.6 \pm 5.8\%$

20 ($\text{mean} \pm \text{SEM}$, $n=6$), but had no effect on the fractional component that was bumetanide-sensitive (88 ± 3.2 vs $75.2 \pm 12.7\%$ total uptake, $\text{mean} \pm \text{SEM}$). Taken together, these data strongly suggest that clotrimazole does not affect Cl^- secretion in T84 cells via inhibition of either apical membrane Cl^- channels or basolateral membrane NaK2Cl cotransporters.

25 **Example 4: Clotrimazole inhibits Chloride secretion by inhibiting K^+ efflux through basolateral K^+ channels in T84 cells.**

30 Methods

1. Clotrimazole inhibits chloride secretion by blockade of K^+ transport through both Ba^{++} -sensitive and thapsigargin-sensitive channels

⁸⁶Rb Efflux Studies

Confluent monolayers on 5 cm² Transwell inserts were used 10-14 days after plating.

⁸⁶Rb flux was measured as an indicator of apical Cl⁻, channel and basolateral K⁺ channel activity as previously described (Venglarik, et al, *Am. J. Physiol. (Cell Physiol. 28)*:C358-C364 (1990).

- 5 Monolayers were preincubated at 37° C with 4 µCi/ml ⁸⁶Rb in HBSS for 90 minutes, with 33 µM clotrimazole absent or present during the final 30 minutes of this 90 min preincubation period. clotrimazole pretreatment did not alter ⁸⁶Rb loading of the cells. One ml samples were obtained and replaced from the basolateral reservoir. After four baseline samples were obtained, the cells were treated (at t = 8 minutes) with vasoactive intestinal peptide (VIP, 5 µM) or
- 10 thapsigargin (5 µM) to stimulate Cl⁻ secretion, and an additional 15 timed samples were obtained. Finally, the cell monolayer was rinsed, cut with its support from the polystyrene ring, and the residual cell-associated radioactivity was determined. Monolayers were maintained at 37° C in room air throughout the study. ⁸⁶Rb was counted by scintillation counting and normalized to percent total uptake as previously described (Venglarik, et al, *Am. J. Physiol. (Cell*
- 15 *Physiol. 28)*:C358-C364 (1990).

Results

- K⁺ channel activity was estimated by measurement of ⁸⁶Rb efflux. clotrimazole was found to significantly inhibit the rate of ⁸⁶Rb efflux after treatment with the cAMP agonist VIP (5
- 20 µM). The rate constant for VIP-stimulated ⁸⁶Rb efflux was reduced by 87% in monolayers treated with clotrimazole (0.0062 vs. 0.0465 % uptake/minute, n=2 in triplicate). clotrimazole inhibited to a similar degree ⁸⁶Rb efflux from monolayers stimulated with thapsigargin (panel B, rate constants 0.011 vs. 0.048% uptake/minute, n=2), suggesting that clotrimazole can inhibit Cl⁻ secretion by blockade of K⁺ transport through both Ba⁺⁺-sensitive and charybdotoxin-
- 25 sensitive channels.

2. Clotrimazole inhibits chloride secretion through distinct cAMP and Ca⁺⁺ sensitive basolateral K⁺ channels

- Selective membrane Permeabilization and Measurement of Potassium Conductance of the Basolateral Membrane.* The basolateral potassium conductance was measured using the
- 30 technique developed by Dawson and co-workers. A potassium gradient (mucosal to serosal) was first established across the monolayer using asymmetric mucosal and serosal buffers containing K⁺ as the sole permeant ion. The addition of amphotericin B (20 µM) to the mucosal reservoir

forms conductive pores in the apical membrane, and thus removes all resistance to transepithelial potassium movement across this membrane. Thus, under the conditions of the experiment, in which the monolayer is short circuited (i.e., voltage-clamped at zero potential) and the transepithelial potassium gradient is constant, the amphotericin-dependent I_{sc} becomes a
 5 measure of the rate of the transepithelial potassium flux across basolateral membranes. Changes in short circuit current (I_{sc}), then represent changes in basolateral K^+ conductances (g_K). I_{sc} and K^+ conductances were measured using calomel electrodes, 3M KCl-agar bridges, and a voltage clamp (University of Iowa, Iowa City). To generate a voltage-current channel relationships, currents were elicited by 1 sec test potentials from -80 to +80 in 10 mV increments in the
 10 asymmetrical high K^+ gluconate solution.

Calculation of basolateral membrane K^+ permeability: Membrane permeabilities were calculated according to the formula:

$$P_K = (cm/s) = J_K (mM/cm^2 \cdot s) / \Delta [K^+] (mM/cm^3)$$

where $\Delta [K^+]$ is equal to the difference in K^+ concentration (135 mM) between the asymmetric
 15 apical and basolateral bathing solutions. Maximal I_{sc} values were converted into K^+ fluxes by dividing by the Faraday constant F (96,500 coulombs/mol) as previously described (Huflejt et al., *J. Clin. Invest.* 93: 1900-1910 (1994)).

Results

20 Basolateral K^+ transport was examined in T84 monolayers permeabilized apically by pretreatment with amphotericin B. Apical and basolateral buffers contained K^+ as the sole permeant ion. All studies were performed with a 135 mM basolaterally directed K^+ gradient. This method has been utilized previously to examine both Cl^- and K^+ transport in T84 cells and HT29-Cl.16E cells. Briefly, ion conductances in the luminal or basolateral membranes of
 25 confluent T84 cell monolayers can be assessed separately by selectively permeabilizing the apical or basolateral membrane using the ionophore amphotericin B. This artificially removes all electrical resistance to ion transport across the plasma membrane containing pores formed by amphotericin B. As a result, the intact contralateral plasma membrane becomes rate limiting for transepithelial ion transport. Agonist-dependent changes in ion conductances can be assessed
 30 directly either as transepithelial short circuit current (I_{sc}) in the presence of established ion gradients, or as transepithelial conductance (G) in the presence of established transepithelial potentials.

K⁺ transport was measured at baseline and after the ordered additions of cAMP- and Ca⁺⁺-agonists. The initial permeabilization with amphotericin B was associated with $49 \pm 19\%$ increase in conductance. Pores formed by amphotericin B display selectivity for monovalent cations. Ca⁺⁺ remained relatively impermeant as evidenced by the small steady state increase in I_{sc} and G_K caused by apical permeabilization with amphotericin B. Given this low baseline I_{sc} and G_K, both cAMP- and Ca⁺⁺-sensitive K⁺ permeabilities (PK) were readily apparent after agonist stimulation. Treatment with the cAMP-agonist forskolin (10 μ M) caused a brisk increase in K⁺ transport through apparently low-conductance pathway(s), as evidenced by symmetrical increases in I_{sc} and G. Carbachol also increased K⁺ currents. The magnitude of the carbachol-induced I_{scK}, however, was similar whether carbachol was added alone or after forskolin (111.7 ± 7.4 vs. $180.7 \pm 15.7 \mu\text{A}/\text{cm}^2$ respectively). Thus, there was no clear evidence of synergy between cAMP and Ca⁺⁺ mediated K⁺ pathways, as would be expected in an apically permeabilized cell system. Analogous to our previous findings in intact T84 monolayers, the forskolin-induced changes in I_{sc} were sustained while the effect of carbachol was short-lived. Both I_{scK} and G_K returned to baseline values within 5 min after addition of carbachol.

Formal current/voltage (I/V) relations were defined before and after agonist stimulation to confirm that both cAMP- and Ca⁺⁺-dependent currents were elicited at physiologic membrane potentials. Thapsigargin was used in place of carbachol as a Ca⁺⁺-agonist in these studies because the K⁺ transients elicited by thapsigargin achieve steady state conductances of much longer duration, as in intact monolayers. It was found that under conditions of basolaterally directed K⁺ gradients, both forskolin and thapsigargin activate macroscopic outwardly rectified (mucosal to serosal) currents at positive transepithelial voltages. Experimental I/V relations obtained after forskolin and thapsigargin stimulation displayed reversal potentials (-40 mV) that approximated the calculated Nernst-potential (-85 mV calculated as $RT/zQ_0 \log [\text{Na}]_{\text{out}}/[\text{Na}]_{\text{in}}$). These results are consistent with the activation of distinct cAMP- and Ca⁺⁺-sensitive basolateral membrane K⁺ conductances in conjunction with one or more nonspecific transepithelial ion shunts, possibly occurring through intercellular tight junctions or basolateral membrane "leaks."

To confirm that the observed changes in I_{sc} and G represented K⁺ transport through K⁺ selective pathways, the effect of forskolin and carbachol on T84 monolayer conductances were examined using buffers containing Na⁺ as the sole permeant cation. These studies were performed using an analogous 135 mM basolaterally directed cation (Na⁺) gradient. Increases in

Isc and G were not detectable in the absence of K⁺. Thus, the increases in cation conductances induced by agonist stimulation are specific to K⁺ transport.

Two pharmacologically distinct K⁺ efflux pathways have been previously identified in intact T84 cells. One pathway participates in the secretory response to cAMP-dependent agonists and displays sensitivity to Ba⁺⁺ salts. The other K⁺ efflux pathway mediates the response to Ca⁺⁺-dependent agonists, and is Ba⁺⁺-insensitive. These findings were confirmed in the permeabilized cell model. The cAMP-sensitive I_K (elicited by treatment with forskolin, 10 μM) was inhibited by greater than 70% by the addition of BaCl₂ (3 mM) to basolateral reservoirs. Ba⁺⁺, however, had no detectable effect on K⁺ transport induced by the subsequent addition of carbachol (100 μM) to the same monolayers. In contrast, when permeabilized monolayers were treated first with carbachol, the induced Ca⁺⁺ I_K was inhibited by 50% by pretreatment with the scorpion venom charybdotoxin (100 nM). Charybdotoxin, however, had no detectable effect on K⁺ transport induced by the subsequent addition of forskolin. Thus in permeabilized cells, the differential sensitivity of K⁺ transport to inhibition by the K⁺ channel blockers BaCl₂ and charybdotoxin paralleled exactly the effect of these channel selective inhibitors on K⁺ transport in intact cells (measured indirectly as a Cl⁻ current).

Taken together, these studies define the permeabilized T84 cell model, and provide strong evidence that under the defined conditions both Isc and G represent K⁺ transport through distinct cAMP- and Ca⁺⁺-sensitive basolateral K⁺ channels.

20 3 Clotrimazole and 2-chlorophenyl-bis-phenyl methanol, a structurally related stable metabolite, inhibit K⁺ transport through both cAMP- and Ca⁺⁺-dependent K⁺ channels

We next tested the hypothesis that clotrimazole may inhibit directly basolateral membrane K⁺ channels in human intestinal T84 cells, as it does in the red cell. clotrimazole significantly inhibited the time course of K⁺ transport after treatment with the cAMP agonist forskolin (10 μM) and the Ca⁺⁺ agonist carbachol (100 μM). Formal IV relations taken at steady state after cAMP or Ca⁺⁺ stimulation confirm that clotrimazole affected both cAMP- and Ca⁺⁺-sensitive channels. Nearly identical results were obtained with 2-chlorophenyl-bis-phenyl methanol. clotrimazole and its metabolite 2-chlorophenyl-bis-phenyl methanol inhibit directly both cAMP- and Ca⁺⁺-sensitive intestinal K⁺ channels indicating that the ring structure in the absence of the imidazole ring sufficient (and perhaps necessary) for this bioactivity.

30 4. Clotrimazole targets the basolateral rather than the apical surface of T84 cells

Methods

Measurement of Cl⁻ Conductance of the Apical Plasma Membrane: To examine apical Cl⁻ conductances, Cl⁻ was used as the sole permeant ion using identical apical and basolateral buffer solutions. Monolayers were permeabilized basolaterally by the addition of 100 μ M Amphotericin B to the serosal reservoir. Generation of voltage-current curves of channel currents were elicited by 1 sec test potentials from -80 to + 80 mV in 10 mV increments in symmetrical high Choline Cl⁻ buffers.

Results

Studies were performed to determine whether the primary target of clotrimazole was located on the basolateral or apical cell surfaces. Most rapid inhibition was achieved by incubation with clotrimazole on both sides of the monolayer. However, basolateral application alone was almost as effective as incubation on both sides. Additionally, the apparent potency of inhibition of clotrimazole at a fixed time point was found to be greater when applied basolaterally than apically. This preferential action of clotrimazole at the basolateral surface of the cell is consistent with the hypothesis that its principal targets are basolateral K⁺ channels.

To confirm these findings, we examined Cl⁻ transport in T84 cell monolayers permeabilized basolaterally with pores formed by amphotericin B. These studies were performed with Cl⁻ as the only permeant anion, and with symmetrical apical and basolateral Cl⁻ concentrations (142 mM). In monolayers not treated with clotrimazole, the addition of forskolin (10 μ M) to basolateral reservoirs increased Cl⁻ conductances significantly over baseline, presumably via activation of the cystic fibrosis transmembrane regulator (CFTR) Cl⁻ channel. In contrast to the clear inhibitory effects of clotrimazole on basolateral K⁺ conductances, however, clotrimazole had no detectable effect on either forskolin- or thapsigargin-stimulated Cl⁻ conductances. I/V relations for Cl⁻ transport were nearly identical in monolayers treated or not treated with clotrimazole. These data provide further evidence that clotrimazole inhibits Cl⁻ secretion in intact T84 cell monolayers by affecting specifically basolateral K⁺ channels. Apical membrane Cl⁻ channels are not inhibited.

Example 5: Clotrimazole inhibits Cl⁻ secretion *in vivo*.

I. Ussing chamber studies using rabbit colonic mucosa:

Methods

4 male, New Zealand rabbits (2.5 kg) were anesthetized by an intravenous injection of pentobarbital (0.5 ml/kg). A 15 cm length of distal colon was removed and opened longitudinally. External muscle layers were removed by blunt dissection and colonic mucosal preparations were mounted in an Ussing chamber (DCTSYS; Precision Instrument Design, CA; 10.3 cm² surface area) and incubated with buffer solution containing (in mM): NaCl 122.0, CaCl₂, 2.0; MgSO₄, 1.3; KCl, 5.0, glucose, 20; NaHCO₃, 25.0 (pH when gassed with 95% O₂/5% CO₂; temperature was maintained at 37°C) with and without clotrimazole (30 μM). The volume of fluid on each side of the mucosa was 7 ml.

Potential difference and I_{sc} were monitored continuously and registered every 10 minutes. Luminal and serosal buffer solutions were interfaced via Ag-AgCl electrodes (Voltage/Current Clamp, Model VCC600, Physiologic Instruments, Inc., San Diego, CA, USA) and Ringer/agar bridge to voltage clamp device (model DVC-1000; Voltage/Current Clamp, World Precision Instruments, Inc.). Resistance (R) was calculated using Ohm's law and the I_{sc} and is given in Ω x cm². After stable baseline resistance and I_{sc} values had been obtained, mucosal preparations were incubated in the presence or absence of serosal clotrimazole (30 μM) for 30 min, and then stimulated by the addition of forskolin (10 μM) or carbachol (10 μM) to the serosal reservoir.

Results

To test the ability of clotrimazole to block K⁺ channels and thus Cl⁻ secretion in native intestinal tissue, we mounted isolated preparations of rabbit colonic mucosa in Ussing chambers containing modified Ringer's solution with or without clotrimazole (30 μM). After I_{sc} had stabilized, successive additions of forskolin (10 μM) and then carbachol (100 μM) were applied to serosal reservoirs, and I_{sc} and G were monitored continuously. Clotrimazole inhibited strongly the time course of forskolin induced I_{sc}. Carbachol had no further effect on I_{sc} in this system.

2. Murine model of secretory diarrhea:

Methods

Treated and control, untreated, mice were gavage fed either clotrimazole (150 mg/kg/day divided in two equal doses, dissolved in peanut oil at a concentration of 20 mg/ml) or vehicle control over a 7 day loading period. Mice were then challenged by gavage with either 25 μg purified cholera toxin (Calbiochem, San Diego, CA) in PBS, vehicle control alone (PBS without

cholera toxin), or cholera toxin in PBS containing 30 μ M clotrimazole. Animals were sacrificed after 5 hours in an uncrowded CO₂ hood. The carcass was weighed, the abdomen was opened, and ligatures were tied at the proximal duodenum and distal rectum. The intestinal block was dissected free of supporting structures and removed as a single unit and weighed. Small and
5 large intestinal segments were normalized to body weight (intestinal weight/carcass weight) for each animal.

Results


To examine whether clotrimazole may inhibit intestinal secretion in vivo, we utilized a murine model of secretory diarrhea. Balb/C mice were gavage fed 150 mg/kg/day clotrimazole,
10 divided into two equal doses, or vehicle control every 12 h for 7 days and subsequently challenged orally with purified cholera toxin (25 μ g). Five hours after treatment with cholera toxin, the mice were sacrificed and intestinal fluid secretion assessed gravimetrically. Pretreatment with clotrimazole reduced by 86% intestinal fluid secretion induced by cholera toxin. Clotrimazole had no effect on intestinal secretion in the absence of cholera toxin. Thus,
15 clotrimazole effectively treated secretory diarrhea in vivo, presumably by inhibiting basolateral K⁺ channels of crypt epithelial cells.

Each of the foregoing patents, patent applications and references is herein incorporated by reference in its entirety. Having described the presently preferred embodiments, in accordance with the present invention, it is believed that other modifications, variations and
20 changes will be suggested to those skilled in the art in view of the teachings set forth herein. It is, therefore, to be understood that all such variations, modifications, and changes are believed to fall within the scope of the present invention as defined by the appended claims.

We claim:

Claims




1. The use of an aromatic compound in the manufacture of a medicament for the treatment of diarrhea, wherein the aromatic compound has the general formula :



wherein $n = 0-3$; wherein $p = 0$ or 1 ; wherein X is selected from the group consisting of $(\text{CH}_2)_m$ ($m=0,1,2$, or 3), $\text{CH}=\text{CH}$, $\text{C}\equiv\text{C}$, SCH_2 , OCH_2 , and NOCH_2 ; wherein R' is selected from the group consisting of H , OH , SH , NO_2 , CN , CHO , ONH_2 , CCH , COR'' , CO_2H , $\text{CO}_2\text{R}''$, OR'' , SR'' , $\text{NR}''\text{R}''$, $\text{CONR}''\text{R}''$, heteroaryl, and $\text{CONR}''(\text{OCH}_3)$; wherein Ar^1 is selected from the group consisting of phenyl, substituted phenyl, and heteroaryl; wherein Ar^2 is selected from the group consisting of phenyl and substituted phenyl; wherein Ar^3 is selected from the group consisting of phenyl, substituted phenyl, biphenyl, bibenzyl, and naphthyl; wherein the phenyl substituent is selected from the group consisting of Cl , F , Br , I , R , OR'' , SR'' , NO_2 , CN , CF_3 , $\text{NR}''\text{R}''$, and CO_2R ; wherein R is selected from the group consisting of straight chain alkyl of $\text{C}_{z(z=1-5)}$, substituted straight chain alkyl of $\text{C}_{z(z=1-5)}$, branched alkyl of $\text{C}_{z(z=1-5)}$, and substituted branched alkyl of $\text{C}_{z(z=1-5)}$; wherein the alkyl substituent is selected from the group consisting of Cl , Br , F , I , OH , OCH_3 , SH , SCH_3 , NH_2 , NHCH_3 , and $\text{N}(\text{CH}_3)_2$; and wherein R'' is selected from the group consisting of hydrogen and R .

2. The use as recited in claim 1, wherein the aromatic compound is clotrimazole.

3. The use as recited in claim 1, wherein the aromatic compound is selected from the group consisting of:




4. The use as recited in claim 1, wherein the aromatic compound is administered orally.

5. The use as recited in claim 1, wherein the subject is a human.


6. The use as recited in claim 5, further comprising administering an anti-diarrheal agent to the subject.

7. The use as recited in claim 6, wherein the anti-diarrheal agent is an oral rehydration fluid.

8. The use as recited in claim 1, wherein the aromatic compound is 2-chlorophenyl-bis-phenyl-methanol and has the following formula:



9. A veterinary preparation comprising:
an aromatic compound in an amount effective to inhibit scours in a subject, the aromatic compound having the general formula:



wherein $n = 0-3$; wherein $p = 0$ or 1 ; wherein X is selected from the group consisting of $(\text{CH}_2)_m$ ($m = 0, 1, 2, \text{ or } 3$), $\text{CH}=\text{CH}$, $\text{C}\equiv\text{C}$, SCH_2 , OCH_2 , and NOCH_2 ; wherein R' is selected from the group consisting of H , OH , SH , NO_2 , CN , CHO , ONH_2 , CCH , COR'' , CO_2H , $\text{CO}_2\text{R}''$, OR'' , SR'' , $\text{NR}''\text{R}''$, $\text{CONR}''\text{R}''$, heteroaryl, and $\text{CONR}''(\text{OCH}_3)$; wherein Ar^1 is selected from the group consisting of phenyl, substituted phenyl, and heteroaryl; wherein Ar^2 is selected from the group

consisting of phenyl and substituted phenyl; wherein Ar^3 is selected from the group consisting of phenyl, substituted phenyl, biphenyl, bibenzyl, and naphthyl; wherein the phenyl substituent is selected from the group consisting of Cl, F, Br, I, R, OR'' , SR'' , NO_2 , CN, CF_3 , $NR''R''$, and CO_2R ; wherein R is selected from the group consisting of straight chain alkyl of $C_{z(z=1-5)}$,

- 5 substituted straight chain alkyl of $C_{z(z=1-5)}$, branched alkyl of $C_{z(z=1-5)}$, and substituted branched alkyl of $C_{z(z=1-5)}$; wherein the alkyl substituent is selected from the group consisting of Cl, Br, F, I, OH, OCH_3 , SH, SCH_3 , NH_2 , $NHCH_3$, and $N(CH_3)_2$; and wherein R'' is selected from the group consisting of hydrogen and R; and,

an anti-scours agent.

10

10. A veterinary preparation as in claim 9, wherein the aromatic compound is clotrimazole.

11. The veterinary preparation as in claim 9, wherein the anti-scours agent is a
15 colostrum extract.

12. The veterinary preparation as in claim 9, wherein the anti-scours agent is an immunological preparation of colostrum.

20 13. The veterinary preparation as in claim 9, wherein the anti-scours agent is a microorganism specific immunological preparation.

14. The veterinary preparation as in claim 9, wherein the anti-scours agent is an oral rehydration fluid.


25

15. The veterinary preparation as in claim 9, wherein the anti-scours agent is a replacement electrolyte composition.

16. The veterinary preparation as in claim 9, wherein the anti-scours agent is an
30 antibiotic composition.


17. The veterinary preparation as in claim 9, wherein the veterinary preparation is a dry preparation.

18. The veterinary preparation as in claim 9, wherein the aromatic compound is 2-chlorophenyl-bis-phenyl-methanol and has the following formula:



10

19. A pharmaceutical preparation, comprising:
 15 an aromatic compound in an amount effective to inhibit diarrhea, the aromatic compound having the general formula:




20

25 wherein $n = 0-3$; wherein $p = 0$ or 1 ; wherein X is selected from the group consisting of $(\text{CH}_2)_m$ ($m = 0, 1, 2$, or 3), $\text{CH}=\text{CH}$, $\text{C}\equiv\text{C}$, SCH_2 , OCH_2 , and NOCH_2 ; wherein R' is selected from the group consisting of H , OH , SH , NO_2 , CN , CHO , ONH_2 , CCH , COR'' , CO_2H , $\text{CO}_2\text{R}''$, OR'' , SR'' , $\text{NR}''\text{R}''$, $\text{CONR}''\text{R}''$, heteroaryl, and $\text{CONR}''(\text{OCH}_3)$; wherein Ar^1 is selected from the group consisting of phenyl, substituted phenyl, and heteroaryl; wherein Ar^2 is selected from the group consisting of phenyl and substituted phenyl; wherein Ar^3 is selected from the group consisting of phenyl, substituted phenyl, biphenyl, bibenzyl, and naphthyl; wherein the phenyl substituent is selected from the group consisting of Cl , F , Br , I , R , OR'' , SR'' , NO_2 , CN , CF_3 , $\text{NR}''\text{R}''$, and CO_2R ; wherein R is selected from the group consisting of straight chain alkyl of $\text{C}_{z(z=1-5)}$, substituted straight chain alkyl of $\text{C}_{z(z=1-5)}$, branched alkyl of $\text{C}_{z(z=1-5)}$, and substituted branched alkyl of $\text{C}_{z(z=1-5)}$; wherein the alkyl substituent is selected from the group consisting of Cl , Br , F ,
 35

I, OH, OCH₃, SH, SCH₃, NH₂, NHCH₃, and N(CH₃)₂; and wherein R'' is selected from the group consisting of hydrogen and R; and,
an anti-diarrheal agent.

- 5 20. The pharmaceutical preparation as in claim 19, wherein the aromatic compound is 2-chlorophenyl-bis-phenyl-methanol and has the following formula:

10



15

21. The pharmaceutical preparation as in claim 19, wherein the aromatic compound is clotrimazole.

22. The pharmaceutical preparation as in claim 19, wherein the anti-diarrheal agent is an oral rehydration fluid.

23. The pharmaceutical preparation as in claim 19, wherein the anti-diarrheal agent is
20 an antibiotic.

24. The pharmaceutical preparation as in claim 19, wherein the anti-diarrheal agent is an electrolyte composition.

- 25 25. The pharmaceutical preparation as in claim 19, wherein the anti-diarrheal agent is an immunoglobulin preparation from bovine colostrum.


26. The pharmaceutical preparation as in claim 19, wherein the anti-diarrheal agent is an oral sugar-electrolyte solution.

30

27. The use of an aromatic compound in the manufacture of a medicament for the treatment of diarrhea, wherein the aromatic compound is selected from the group consisting of miconazole and econazole.

5 28. A method for treating scours, the method comprising the step of:
administering to a subject in need of such treatment, an aromatic compound in an amount effective to inhibit scours, wherein the aromatic compound is selected from the group consisting of miconazole and econazole.

10 29. A method for treating scours, the method comprising the step of:
administering to a subject in need of such treatment, an aromatic compound in an amount effective to inhibit scours, wherein the aromatic compound has the general formula :




20 wherein n= 0-3; wherein p= 0 or 1; wherein X is selected from the group consisting of (CH₂)_m (m=0,1,2, or 3), CH=CH, C≡C, SCH₂, OCH₂, and NOCH₂; wherein R' is selected from the group consisting of H, OH, SH, NO₂, CN, CHO, ONH₂, CCH, COR'', CO₂H, CO₂R'', OR'', SR'', NR''R'', CONR''R'', heteroaryl, and CONR''(OCH₃); wherein Ar¹ is selected from the group
25 consisting of phenyl, substituted phenyl, and heteroaryl; wherein Ar² is selected from the group consisting of phenyl and substituted phenyl; wherein Ar³ is selected from the group consisting of phenyl, substituted phenyl, biphenyl, bibenzyl, and naphthyl; wherein the phenyl substituent is selected from the group consisting of Cl, F, Br, I, R, OR'', SR'', NO₂, CN, CF₃, NR''R'', and CO₂R; wherein R is selected from the group consisting of straight chain alkyl of C_{z(z=1-5)},
30 substituted straight chain alkyl of C_{z(z=1-5)}, branched alkyl of C_{z(z=1-5)}, and substituted branched alkyl of C_{z(z=1-5)}; wherein the alkyl substituent is selected from the group consisting of Cl, Br, F,

I, OH, OCH₃, SH, SCH₃, NH₂, NHCH₃, and N(CH₃)₂; and wherein R'' is selected from the group consisting of hydrogen and R.

30. The method for treating scours as in claim 29, wherein the aromatic compound is
5 clotrimazole.

31. The method for treating scours as in claim 29, wherein the aromatic compound is selected from the group consisting of:




32. The method for treating scours as in claim 29, wherein the aromatic compound is administered orally.

33. The method for treating scours as in claim 29, wherein the subject is selected from the group consisting of a horse, a cow, a pig, and a goat.


20

34. The method for treating scours as in claim 29, further comprising administering an anti-scours agent to the subject.


35. The method for treating scours as in claim 29, wherein the aromatic compound is
25 2-chlorophenyl-bis-phenyl-methanol and has the following formula:



1/2

**Fig. 1**

2/2

**Fig. 2**